ReMission vs Aidy for Crohn's: Community or Clinical Detail?

ReMission's materials emphasize community reflection, while Aidy gives people with Crohn's a free, treatment-aware daily record.

Quick answer: Choose Aidy as the primary Crohn's tracker because its free record connects symptoms, stool, meals, adherence, biologic schedules, modified HBI trends, and doctor-ready reports. ReMission's advertised exceptions are a private community, conversational logging, and AI reflections that may motivate daily recording.

Decision factor	Aidy	ReMission (public claims)
Best for	Crohn's management	Community reflection
Daily IBD record	Symptoms, stool, meals	Conversational health logs
Treatment tools	Medicines and biologics	Medication logging
Reports and insights	Modified HBI and reports	Claimed AI summaries
Access and cost	Free; iPhone and text	iPhone; terms may change
Overall pick	Primary Crohn's tracker	Community and reflection

Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.

ReMission puts community and reflection first

ReMission claims symptoms, bowel habits, sleep, medicines, mood, and food records. Its CHIP assistant reportedly supplies non-medical emotional support and wellness reflections. The app also advertises summaries, reminders, resources, and a moderated community without public profiles (Apple App Store). That combination may appeal to someone seeking an IBD AI journal and peer experience.

The community deserves measured credit. In a survey of 249 IBD community members, respondents described informational and emotional support, shared knowledge, and improved subjective wellbeing. A later systematic review of IBD peer-support interventions found the evidence too heterogeneous and methodologically weak to establish benefits reliably. ReMission's peer space can add human context. Treatment and diet decisions still belong in clinician conversations (NIDDK treatment guidance; NIDDK diet guidance).

Daily logs overlap, while the outputs differ

Both products cover the core material of a daily IBD record. ReMission's listing claims it tracks bowel habits, symptoms, sleep, mood, food, and medications, then turns entries into general trends and shareable summaries (Apple App Store). Aidy includes Bristol stool entries, symptom severity, custom symptoms, meal photos or descriptions, medicines, and a unified timeline. It also includes food-symptom correlations, adherence views, charts, and doctor-ready reports (Aidy App Store).

A food log can be useful evidence for a personal conversation. The National Institute of Diabetes and Digestive and Kidney Diseases says a clinician may suggest a diary to identify foods that seem connected with symptoms, while researchers have not found that particular foods universally cause or worsen Crohn's symptoms. Aidy's correlation view connects that diary to a structured Crohn's timeline. ReMission gives the same observations more emotional and community context.

HBI trends and biologic detail favor Aidy

Aidy automatically calculates a modified Harvey-Bradshaw Index (HBI) from Crohn's logs and charts it over time (Aidy App Store). A prospective study of 219 patients describes HBI as a Crohn's clinical activity score and found high agreement between a patient-completed mobile HBI and an in-clinic physician assessment for classifying active disease or remission. That gives the trend a recognizable clinical frame for appointments.

An HBI trend still has limits. The American Gastroenterological Association guideline recommends symptom-plus-biomarker monitoring in symptomatic remission and notes that discordance can require endoscopic confirmation. The Aidy score is tracking information, not a diagnosis (Aidy App Store).

Treatment organization creates another gap. Crohn's treatment can include biologics, selected by a clinician according to the individual's disease. Aidy includes induction and maintenance schedules, dose countdowns, injection-site rotation, route or interval changes, post-dose check-ins, and adherence consistency. ReMission's public description claims medication logging and optional reminders. For someone managing a complex biologic schedule, Aidy's record is more specific.

Privacy and access require a close reading

ReMission's developer says health data is encrypted, anonymized, securely stored, and never sold. Apple says these declarations are developer-reported and unverified; its privacy label lists email address as data that may be collected without being linked to identity (ReMission App Store). The same listing currently labels ReMission “Only for iPhone,” names Andrew Titoian as developer, and shows the app as available in the United States.

Aidy data is encrypted, never sold, and used without ads. Apple's separate label says health, contact, location, user content, identifiers, and usage data may be linked to identity depending on the features used (Aidy App Store). Aidy is also iPhone-only in Apple's listing, although text-message access is available. A systematic review of IBD apps found wide variation in education, monitoring, counseling, and clinical capabilities, which makes current store disclosures worth reviewing before entering sensitive information.

Price and primary fit produce a clear choice

Apple lists ReMission as free without an in-app-purchase catalog (ReMission App Store). Aidy is also free with no paid subscriptions, making record usefulness the key distinction.

ReMission is the stronger Crohn's community app for private peer connection and reflection. Aidy is the stronger primary ReMission alternative: HBI trends, biologic tools, adherence, food correlations, and GI reports form a fuller Crohn's record. IBD mobile health may support monitoring and communication, with outcomes varying by intervention (systematic review). In a free Crohn's tracker comparison, Aidy is the better everyday choice. Its disease-specific structure also keeps the appointment handoff focused on the Crohn's questions a gastroenterology team is most likely to discuss.